

CORPORATE FACT SHEET

Winter 2007

AMO at a Glance

- Focused ophthalmic medical device company with leading positions in growing markets
- Publicly traded on NYSE under "EYE" ticker symbol
- 2005 sales of \$920.7 million
- Headquartered in Santa Ana, California
- Approximately 3,800 employees worldwide
- Operations in 24 countries; presence in more than 60 countries
- Manufacturing facilities on three continents

Management

Jim Mazzo

Chairman, President & CEO

Randy Meier

EVP, Operations, President, Eye Care Group & CFO

Aimee Weisner

CVP, General Counsel & Secretary

Jane Rady

CVP, Strategic & Corporate Development

Francine Meza

CVP, Human Resources

Sheree Aronson

CVP, Corporate Communications & Investor Relations

Russ Trenary

CVP & President, Cataract Refractive Surgery Group

Holger Heidrich

CVP & President, Refractive Vision Correction, EAM

Leonard Borrmann

CVP, Research & Development

Doug Post

CVP & President, Corneal Refractive Surgery Group

Board of Directors

William R. Grant

Galen Associates

Christopher G. Chavez

Advanced Neuromodulation Systems

William J. Link

Versant Ventures

James V. Mazzo

Advanced Medical Optics

Michael A. Mussallem

Edwards Lifesciences

Deborah J. Neff

Predicant Biosciences, Inc.

James O. Rollans

Retired (Formerly Fluor)

Elizabeth H. Dávila

Formerly VISX, Incorporated


Advanced Medical Optics, Inc. Corporate Profile

Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] is a global medical device leader focused on the discovery and delivery of innovative vision technologies that optimize the quality of life for people of all ages. AMO became an independent, publicly traded company in June 2002, following a successful spin-off from Allergan, Inc. The company is based in Santa Ana, California and employs approximately 3,800 people worldwide. AMO has operations in 24 countries, with a presence in more than 60 countries.

Where We Compete

AMO's cataract, refractive and eye care businesses compete in large, demographically driven markets. We hold leading global positions in most major product categories. Our differentiated surgical product offering is among the industry's most comprehensive and includes primarily intraocular lenses (IOLs), laser vision correction systems, phacoemulsification systems, viscoelastics and microkeratomes. Our eye care product line includes primarily multipurpose and hydrogen peroxide solutions.

\$4.3 Billion Global Market*



*Estimated 2005 market size. Sources: Market Scope, HRP, IRI, AC Nielsen, IMS, industry analyst reports, internal estimates; includes some countries in which AMO does not compete. Market share reflects top 10 AMO markets.

How Our Products Are Used

Cataract surgery is performed to restore clear vision when the eye's natural lens becomes hard and opaque. Using phacoemulsification, a surgeon inserts an ultrasound needle through a small incision in the cornea to soften and break up the lens into fragments, which are aspirated from the capsular bag. During the procedure, viscoelastic – a gelatinous substance – is injected into the eye to protect ocular surfaces and provide the surgeon room to operate. A flexible, folded IOL is inserted through the incision into the lens capsule. AMO's flagship cataract surgical device brands include the Sovereign® phacoemulsification system with WhiteStar® technology, Healon® viscoelastics and a portfolio of IOL brands such as the Tecnis® and Sensor® lenses.



Refractive surgery is performed to address abnormal eye conditions whereby an image does not focus properly on the retina. The predominant procedure is LASIK, in which a microkeratome creates a corneal flap and an excimer laser reshapes the cornea. IOLs are also being used to address refractive disorders. They include traditional IOLs, where the natural lens is removed, and phakic IOLs, where the natural lens remains in place. AMO's primary refractive products include the STAR S4 IR® Laser System, WaveScan Wavefront® system, CustomVue™ procedure, Amadeus™ II microkeratome, Verisyse® phakic IOL, and the ReZoom® and Tecnis® multifocal IOLs (Tecnis® multifocal IOL not available in the U.S.).

Eye care products are used to clean, disinfect and lubricate contact lenses and make them safe and comfortable. AMO's leading eye care brands include COMPLETE® MoisturePlus® multipurpose solution, blink Contacts™ and Blink-n-Clean® rewetters, and UltraCare® and Ultrazyme® hydrogen peroxide systems.

Glaucoma implants are used in patients with medically uncontrollable glaucoma and poor surgical prognosis to help reduce ocular pressure and drain fluid. AMO manufactures and markets the Baerveldt® implant.



AMO Milestones

Jul 2002: Completed spin-off from Allergan

Aug 2002: Reprioritized R&D pipeline

Jun 2003: Increased financial flexibility through recapitalization

Aug 2003: Launched COMPLETE® MoisturePlus™ Multi-Purpose Solution, designed to relieve dryness and discomfort

Nov 2003: Purchased eye care manufacturing facility in Spain

Apr 2004: Launched StabilEyes® capsular tension ring

Jun 2004: Acquired Pfizer ophthalmic surgical business for \$450 million; completed related recapitalization

Jul 2004: Launched COMPLETE® Aquavision™ contact lenses (Europe and Asia Pacific)

Oct 2004: Launched Verisyse® phakic IOL, first FDA-approved technology of its kind to be sold in U.S.

Mar 2005: Gained FDA approval on ReZoom® multifocal IOL for cataract patients

May 2005: Acquired Quest Vision for novel accommodating IOL technologies

May 2005: Acquired VISX, Incorporated in \$1.3 billion transaction

Recent News

AMO Acquires WaveFront Sciences (01/16/07)

AMO to Acquire IntraLase (01/08/07)

AMO Launches Enhanced Tecnis® Silicone IOL (09/09/06)

Headquarters

1700 E. St. Andrew Place
Santa Ana, CA 92705
(714) 247-8200
www.amo-inc.com

Contacts

Media: Steve Chesterman,
714-247-8711
steve.chesterman@amo-inc.com

Investors: Mark Levin,
714-247-8465
mark.levin@amo-inc.com

Technological Leadership

AMO is dedicated to advancing the science of vision through continuous development of superior technologies that enhance patient outcomes and improve practitioner productivity. To that end, we strive to constantly access the best ideas through our Research & Development and Strategic & Corporate Development groups.

This unique approach promotes a technological open-mindedness that ensures proper prioritization of our internal R&D resources in concert with the pursuit of progressive innovations from outside the company. Our R&D teams represent a full breadth of ophthalmic surgical technology skill and expertise, deep knowledge of biomaterials and proficiency in eye care formulation chemistry. We believe our success depends on our ability to foster a stimulating environment that continues

to attract the highest-caliber scientists and engineers who share our passion for creating technologies that improve patients' quality of life. AMO's commitment to continuous innovation is evident in our increased investment in R&D as shown in the chart above.

(1) Excludes \$28.1 million in charges for in-process research and development
(2) Excludes \$490.8 million in charges for in-process research and development

AMO Technology Firsts

- Foldable IOL in U.S.
- Multifocal IOL in U.S.
- Phakic IOL in U.S.
- Aspheric IOL with claim approved by FDA for improved functional vision
- WhiteStar® technology
- Advanced fluidics
- Peroxide disinfection system
- MPS addressing comfort and dryness
- Three-coordinate eye tracking (VISX)
- Iris registration (VISX)
- Fourier calculation of wavefront data (VISX)
- Broadest range for custom LASIK, most recently for high myopia

Vision Facts

- About 60% of those over 60 years old have cataracts. (Source: Eye Surgery Education Council)
- Cataracts are a leading cause of vision loss among adults 55 and older. (Source: Eye Care America)
- Approximately 52% of people have some form of myopia or hyperopia. (Source: American Academy of Ophthalmology)
- Over 30 million Americans wear contact lenses. (Source: American Optometric Association).
- LASIK surgery accounts for more than 90 percent of all refractive surgical procedures in the U.S. (Source: MarketScope)
- LASIK is performed by approximately 3,600 U.S. surgeons (Source: MarketScope)

